The importance of brain metastasis in EGFR mutation positive NSCLC patients

Chemotherapy Research and Practice

Volumn 2014, Issue , 2014, Pages

  Noronha, Vanita ^a   Joshi, Amit ^a   Gokarn, Anant ^a   Sharma, Vibhor ^a   Patil, Vijay ^b   Janu, Amit ^a   Purandare, Nilendu ^a   Chougule, Anuradha ^a   Jambhekar, Nirmala ^a   Prabhash, Kumar ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b Malabar Cancer Institute   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PEMETREXED;

ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84942923607     PISSN: 20902107     EISSN: 20902115     Source Type: Journal    
DOI: 10.1155/2014/856156     Document Type: Article

References (19)

1. J. B. Sorensen, H. H. Hansen, M. Hansen, and P. Dombernowsky, "Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis," Journal of Clinical Oncology, vol. 6, no. 9, pp. 1474-1480, 1988.
2. M. A. Chidel, J. H. Suh, J. F. Greskovich, P. A. Kupelian, and G. H. Barnett, "Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis," Radiation Oncology Investigations, vol. 7, no. 5,pp. 313-319, 1999.
3. E. C. A. Kaal,C. G. J. H. Niël, and C. J. Vecht, "Therapeuticmanagement of brain metastasis," The Lancet Neurology, vol. 4, no. 5, pp. 289-298, 2005.
4. R. Porta, J. M. Sánchez-Torres, L. Paz-Ares et al., "Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation," European Respiratory Journal, vol. 37, no. 3, pp. 624-631, 2011.
5. V. R. Bhatt, S. Kedia, A. Kessinger, and A. K. Ganti, "Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptormutations," Journal of Clinical Oncology, vol. 31, no. 25, pp. 3162-3164, 2013.
6. A. Chougule, K. Prabhash, V. Noronha et al., "Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity," PLoS ONE, vol. 8, no. 10, Article IDe76164, 2013.
7. C. H. Gow, C. R. Chien, Y. L. Chang et al., "Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response," Clinical Cancer Research, vol. 14, no. 1, pp. 162-168, 2008.
8. F. Cappuzzo, A. Ardizzoni, H. Soto-Parra et al., "Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)," Lung Cancer, vol. 41, no. 2, pp. 227-231, 2003.
9. F. A. Shepherd, J. R. Pereira, T. Ciuleanu et al., "Erlotinib in previously treated non-small-cell lung cancer,"TheNewEngland Journal of Medicine, vol. 353, no. 2, pp. 123-132, 2005.
10. S. M. Lee, I. Khan, S. Upadhyay et al., "First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebocontrolled, phase 3 trial," The Lancet Oncology, vol. 13, no. 11, pp. 1161-1170, 2012.
11. P. A. Jänne, X. Wang, M. A. Socinski et al., "Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial," Journal of Clinical Oncology, vol. 30, no. 17, pp. 2063-2069, 2012.
12. D.-Y. Kim, K.-W. Lee, T. Yun et al., "Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer," Oncology Reports, vol. 14, no. 1, pp. 207-211, 2005.
13. A. F. Eichler, K. T. Kahle, D. L. Wang et al., "EGFRmutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer," Neuro-Oncology, vol. 12, no. 11, pp. 1193-1199, 2010.
14. K. Hotta, K. Kiura, H. Ueoka et al., "Effect of gefitinib ("Iressa", ZD1839) on brain metastases in patients with advanced nonsmall-cell lung cancer," Lung Cancer, vol. 46, no. 2, pp. 255-261, 2004.
15. J.-E. Kim, D. H. Lee, Y. Choi et al., "Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brainmetastasis," Lung Cancer, vol. 65,no. 3, pp. 351-354, 2009.
16. H. Asahina, K. Yamazaki, I. Kinoshita et al., "A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations," British Journal of Cancer, vol. 95, no. 8, pp. 998-1004, 2006.
17. Y. H. Jung, C. W. Han, Y. D. Jung, Y. Y. Cho, and D. J. Han, "Complete remission of brain metastases in non-small cell lung cancer patients harboring an EGFR mutation treated with tyrosine kinase inhibitor without radiotherapy: a report of 3 cases," Case Reports in Oncology, vol. 7, no. 1, pp. 149-154, 2014.
18. M. Jamal-Hanjani and J. Spicer, "Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain," Clinical Cancer Research, vol. 18, no. 4, pp. 938-944, 2012.
19. H. G. Yi, H. J. Kim, Y. J. Kim et al., "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI," Lung Cancer, vol. 65, no. 1, pp. 80-84, 2009.